Search
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalEndothelin receptor antagonism provides a novel therapeutic pathway for the management of patients with resistant hypertension.
Categories: Endothelin Receptor Antagonists, P-glycoprotein substratesInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalactivity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical studies have shown that PI3K pathway inhibition releases negative feedback and activates receptor
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased do...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations. However, the development of KRAS in...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Fezolinetant, an NK3 receptor antagonist, was developed in response to this issue as well as more understanding of the role of NK3R in the hypothalamic-pituitary-gonadal (HPG) axis. … [A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. … Since they inhibit these mechanisms and desensitize neuronal circuits, the use of CGRP receptor antagonists is beneficial in the treatment of migraine.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigationalIptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulato...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesMaralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalMaralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat. Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, pa...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigationalOdevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC). Odevixibat is the first approv...
Categories: P-glycoprotein substratesTebipenem pivoxil
go.drugbank.com/drugs/DB16840ApprovedTebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. Carbapenems are the standard treatme...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers